Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

NCT03991130 is registered in ClinicalTrials.gov with Gregory Daniels as lead sponsor.

NCT NCT03991130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03991130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Lead sponsor
Gregory Daniels
Phase
Phase 2
Overall status
Terminated
Start date
July 17, 2019
Completion date
August 16, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, renal cell carcinoma, metastatic